

Case Investigation Form Coronavirus Disease (COVID-19)



Version 9

- 1) The Case Investigation Form (CIF) is meant to be administered as an interview by a health care worker or any personnel of the DRU. This is not a self-administered questionnaire.
- 2) Please be advised that DRUs are only allowed to obtain 1 copy of accomplished CIF from a patient.
- 3) Please fill out all blanks and put a check mark on the appropriate box. Never leave an item blank (write N/A). Items with * are required fields. All dates must be in MM/DD/YYYY format.

Disease Reporting Unit*					D	DRU Region and Province					PhilHealth No.*						
testing						adas					asdas						
Name of Interviewer						Contact Number of Interviewer					Date of Interview (MM/DD/YYYY)*						
tetsing123								121312	3								
Name of Informant (if applicable)						elationship				(Contact Number of Informant						
asdasd								sddsaso			242324						
			Not applic		,			•	case classifica	ition		Update dispositi					
If existing car (check all the		I H	Not applic Update sy	•	(nown)				vaccination lab result			Update exposur Others, specify:	e / travel h	istory			
(CHECK UII THE	αι αρριγη		Update sy		ıs / outc	·				findings	_	adsaa					
Type of Clien	nt*					outcome Update chest imaging findings t, Probable, or Confirmed) Close Contact					☐ For RT-PCR Testing (Not a Case of Close Contact)						
Testing Category/Subgroup* (Check all that apply, refer to Appendix 2)												ı 🗆 J					
	Part 1 Patient Information																
Part 1. Patient Information 1.1. Patient Profile																	
Last Name*		rile			l ci	First Name (and Suffix)* -					Middle Name* Eugenio						
						First Name (and Suffix)* Baldwin											
Birthday (MM/DD/YYYY)* 08/05/1996					A	Age*25					Sex*						
Civil Status Married					N	Nationality*											
Occupation a	adadds				W	orks in a closed	l settir	ıg?	☐ Yes		No		☐ Unknown				
1.2. Current Address in the Philippines and Contact Information* (Provide address of institution if patient lives in closed settings, see 1.5)																	
House No./L	.ot/Bldg.*			Street/F	Purok/Sit				arangay*			Municipality/City*					
335					Magdalo					Potol			Kawit				
				Home P	Home Phone No. (& Area Code)				ellphone No.*			Email Address					
Cavite					asadasd 505				Ç	919999		asdasds	s@asddas.com				
1.3. F		_	ss and Conta	ct Inform		ation (if different from current ac							3 G dodddo:00111				
House No./L					eet/Purok/Sitio				arangay			Municipality/Cit	у				
	335				Magdalo					Potol							
					hone No	one No. (& Area Code)			Cellphone No.			Email Address					
	Cavite				as	asadasd 505			919999			asdasds@asddas.com					
	Current Wo	e Address ar	d Contac	t Inform	ation												
Lot/Bldg.				Street					Barangay			Municipality/City					
asddasda				asdas				Potol			Kawit						
Province Name of Wo					f Workp	•			Phone No./Cellphone No.			Email Address					
Cavite adas asdasdads asdasds@asddas.com											.com						
		ulation	1			on exposure and travel history in Part 3)											
Health Care	Worker*		-	name of health facility: asdasdadad						_ and location				No			
Returning Overseas Filipino* Yes, country of original of the country of original original or the country of original or the country					of origin:									No			
Foreign National Traveler* Yes, country of o				of origin:	us			and Passp	ort number: 1	23213			No				
Locally Stranded Individual / Yes, City, Municip			nicipality	ality, & Province of origin <u>asdadadsd</u>							No						
zodany stranaca marriadary					y Stranded Individual Authorized Person Outside Residence / Local Traveler												
				Yes, institution type: <u>qweqwqe</u> and name: <u>adasd</u>									No				
Lives in Closed Settings*						ntial facilities, retirement communities, care homes, camps, etc.)											
Part 2. Case	Investigation	on Deta	aile														
	Consultatio																
		on?	T _©	Yes, Date of First Consult (MM/DD/YYYY)* 11/26/202								No					
						asdadadas											
					<u> </u>	f hospital/isola	tion/a	uaranti	ne facility)								
	ted in hospi								and Time adn	nitted in hospi	tal 11/26/20	21	03:37 pm				
Admitt	ted in isolat	arantine fac	litv asda	dsd	Date and Time isolated/quarantined in facility 11/26/2021 03:37 pm												
_	ne isolation,		,		Date and Time isolated/guarantined at home 11/26/2021 03:37 pm												
_	-			arged: Da	te of Dis	charge /MM/DC)/үүү					addaasda					
Discharged to home If discharged: Date of 2.3. Health Status at Consult* (Refer to Appendix						f Discharge (MM/DD/YYYY)* 11							Critical				
2.4. Case Classification* (Refer to App								Mild	O Mod		O Severe						
	Vaccination			ppenaix 1	,	☐ Suspect		٠	Probable	☐ Confi	rrnea	□ Non-COVID-1	.9 Case				
			ame of Vacci	ne*	Dose n	umber le a 1st 1	2nd*	V	accination cen	ter/facility	Region	of health facility	Adver	se event/s?			
					200011	ose number (e.g. 1 st , 2 nd)*			Vaccination center/facility asddas		asdadadas		Yes	□ No			
11/26/2021			asdad			2nd					as			☑ No			
11/26/2021			tyuit			1st			ghkgjk	i.g	I	ghkkj	Yes	ı⊒ı NO			

2.6. C	linical Info	ormatio	on																
Date of Onse	t of Illness	(MM/	DD/YYY	y)* <u>11/26/2021</u>	Comorbidities (Check all that apply if present)														
Signs and Symptoms (Check all that apply)																			
Asymptomatic Fever 1456 °C Cough General weakness Fatigue				Dyspnea Anorexia Nausea Vomiting Diarrhea					■ None ■ Hypertension □ Diabetes □ Heart Disease □ Lung Disease					Genito-urinary Neurological Disease Cancer					
☐ Headache ☐ Altered Mental Status																 □ No			
☐ Myalgia ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐				osmia (loss of smell, w/ eusia (loss of taste, w/o	High-risk pregnancy? Yes					Ω No									
☐ Coryza ■			_	ners, specify <u>asddasd</u>		Was diagnosed to have Severe Acute Respir					ness?	☐ Yes	(• No					
Chest imaging	findings s	uggesti	ive of C	OVID-19															
Date done	Chest ima			Results															
Chest radiography Chest CT Chung ultrasound None Chest CT: Multiple bilateral ground glass opacities, often rounded in morphology, with peripheral and lower lung dist. Chest CT: Multiple bilateral ground glass opacities, often rounded in morphology, w/ peripheral & lower lung Lung ultrasound: Thickened pleural lines, B lines, consolidative patterns with or without air bronchograms Other findings, specify asddasdas													-						
2.7. Laboratory Information Have tested positive using Wes, date of specimen Collection (MM/DD/YYYY)* 11/26/2021 No																			
RT-PCR before? * Laboratory * adaasd No. of previous RT-PCR swabs done 3																			
Date collected	l* Date re	eleased	d Lak	oratory*							Results*								
11/26/202	11/26/2021 11/26/2021		21	asdasda	0 0 0 0	RT-PCR (NP RT-PCR (OP	RT-PCR (OPS) RT-PCR (NPS) RT-PCR (OPS and NPS) RT-PCR (OPS and NPS) Others: erwrwewr Antigen; reason_rtwerrewrtr brand of kit asddasda Antibody Test							Pending Positive Others: a	⊚ □ sdads	Negative Equivocal sd			
				0 0 0			RT-PCR (OPS)						_ 0	Pending Positive Others:	0	Negative Equivocal			
2.8. Ot	utcome/Co	onditio	n at Tir	ne of Report*															
Active (cur	rently adn	nitted/	isolatio	n/quarantine) 🛭 Red	covered, da	te of recovery	у (М	M/DD/YYYY)*	11/26/202	21	🗆 Died, da	te of	death <i>(мі</i>	м/DD/YYYY)* <u>1</u>	1/26/2	2021			
If died,		Imme	nmediate Cause: adadas						Antecedent Cause: Oijjli										
			rlying Cause: opupoipo					Contributory Conditions: oilihlolio											
				id Travel History					1_										
History of exposure to known probable and/or confirmed COVID-19 case 14 days before of signs and symptoms? OR If Asymptomatic, 14 days before swabbing or specimen confirmed coving the coving t								ollection? * No							_				
				known COVID-19 trans atic. 14 days before sw		,	· · · · · · · · · · · · · · · · · · ·						•						
signs and symptoms? OR If Asymptomatic, 14 days before swabbing or specimen col											_								
19/16/9/1					With o	ngoing COVID	-19	19 community transmission			on? • Yes			□ No					
Airline/Sea vessel				Flight/Vessel Number					Date of departure (MM/DD/YYYY)					Date of arrival in PH (MM/DD/YYYY)					
asdadas asdads									11/26/2					11/26/20	21				
If Local Travel,	, specify tr	avel pla	aces (Cl	neck all that apply, prov	vide name d	f facility, add		<i>, and inclus</i> Address	sive travel				D-4	NACH -		COV/ID 40			
Place Visited				Name of Place	(Region, Pr			pality/City)	Inclusive Travel Dates n: To:			With ongoing COVID-19 Community Transmission							
Health Facility				asdad				asdadad			11/26/2021 11			☐ Yes		No			
Closed Settings				asdad	asdadad				11/	11/26/2021 11/26			6/2021						
□ School											☐ Yes ☐ No								
□ Workplace													□ No						
■ Market				asdad		asdadad				11/26/2021 11/2			26/2021		□ No				
☐ Social Gathering												☐ Yes		⊙ No					
□ Others														☐ Yes		□ No			
■ Transport Service, specify the following:																			
Airline / Sea vessel / Bus line / Tr									Date (MM/DD/YYYY) Destinat										
asdsad			asdadad ewtertwtv				11/26/2021 aswerw					erww	wrwe 11/26/2021						
						Ta. (1)		, ,	.6 ,	1				<u> </u>					
- If symptomatic, provide names and contact numbers of persons who						e the back page if needed)					Contact Number asdsdsads								
were with the patient two days prior to onset of illness until this date - If asymptomatic, provide names and contact numbers of persons who					asdadds ryrtty					fgghhfdfh									
were with the patient on the day specimen was submitted for testing						ryrtty					iggilliulii								
until this date														+					

SUSPECT

A) A person who meets the clinical AND epidemiological criteria

Clinical criteria:

- 1) Acute onset of fever AND cough OR
- Acute onset of ANY THREE OR MORE of the following signs or symptoms; fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia / nausea/ vomiting, diarrhea, altered mental status. AND

- Epidemiological criteria

- Residing/working in an area with high risk of transmission of the virus (e.g closed residential settings and humanitarian settings, such as camp and camp-like setting for displaced persons), any time w/in the 14 days prior to symptoms onset OR
- 2) Residing in or travel to an area with community transmission anytime w/in the 14 days prior to symptoms onset; OR
- Working in health setting, including w/in the health facilities and w/in households, anytime w/in the 14 days prior to symptom onset;

 OR
- B) A patient with severe acute respiratory illness (SARI: acute respiratory infection with history of fever or measured fever of ≥ 38°C; cough with onset w/in the last 10 days; and who requires hospitalization)

PROBABLE

- A) A patient who meets the clinical criteria (on the left) AND is contact of a probable or confirmed case, or epidemiologically linked to a cluster of cases which had had at least one confirmed identified within that cluster
- B) A suspect case (on the left) with chest imaging showing findings suggestive of COVID-19 disease. Typical chest imaging findings include (Manna, 2020):
 - Chest radiography: hazy opacities, often rounded in morphology, with peripheral and lower lung distribution
 - Chest CT: multiple bilateral ground glass opacities, often rounded in morphology, with peripheral and lower lung distribution
 - Lung ultrasound: thickened pleural lines, B lines (multifocal, discrete, or confluent), consolidative
 patterns with or without air bronchograms
- C) A person with recent onset of anosmia (loss of smell), ageusia (loss of taste) in the absence of any other identified cause
- D) Death, not otherwise explained, in an adult with respiratory distress preceding death AND who was a contact of a probable or confirmed case or epidemiologically linked to a cluster which has had at least one confirmed case identified with that cluster

CONFIRMED

A person with laboratory confirmation of COVID-19 infection,

irrespective of clinical signs and symptoms.

Appendix 2. Testing Category / Subgroup

- A Individuals with severe/critical symptoms and relevant history of travel/contact
- Individuals with mild symptoms, relevant history of travel/contact, and considered vulnerable; vulnerable populations include those elderly and with preexisting medical conditions that predispose them to severe presentation and complications of COVID-19
- C Individuals with mild symptoms, and relevant history of travel and/or contact
 - Individuals with **no symptoms** but with **relevant history** of travel and/or contact or high risk of exposure. These include:
- D1 Contact-traced individuals

D

- D2 Healthcare workers, who shall be prioritized for regular testing in order to ensure the stability of our healthcare system
- D3 Returning Overseas Filipino (ROF) workers, who shall immediately be tested at port of entry
- Filipino citizens in a specific locality within the Philippines who have expressed intention to
 return to their place of residence/home origin (Locally Stranded Individuals) may be tested subject to the existing protocols of the IATF
- E Frontliners indirectly involved in health care provision in the response against COVID-19 may be tested as follows:
- E1 Those with high or direct exposure to COVID-19 regardless of location may be tested up to once a week. These include: (1) Personnel manning the Temporary Treatment and Quarantine Facilities (LGU and Nationally-managed); (2) Personnel serving at the COVID-19 swabbing center; (3) Contact tracing personnel; and (4) Any personnel conducting swabbing for COVID-19 testing
- Those who do not have high or direct exposure to COVID-19 but who live or work in Special Concern Areas may be tested up to every two to four weeks. These include the following: (1) Personnel manning Quarantine Control Points, including those from Armed Forces of the Philippines, Bureau of Fire Protection; (2) National / Regional / Local Risk Reduction and Management Teams; (3) Officials from any local government / city / municipality health office (CEDSU, CESU, etc.); (4) Barangay Health Emergency Response Teams and barangay officials providing barangay border control and performing COVID-19-related tasks; (5) Personnel of Bureau of Corrections and Bureau of Jail Penology & Management; (6) Personnel manning the One-Stop-Shop in the Management of ROFs; (7) Border control or patrol officers, such as immigration officers and the Philippine Coast Guard; and (8) Social workers providing amelioration and relief assistance to communities and performing COVID-19-related tasks
- Other vulnerable patients and those living in confined spaces. These include but are not limited to: (1) Pregnant patients who shall be tested during the peripartum period; (2) Dialysis patients; (3) Patients who are immunocompromised, such as those who have HIV/AIDS, inherited diseases that affect the immune system; (4) Patients undergoing chemotherapy or radiotherapy; (5) Patients who will undergo elective surgical procedures with high risk for transmission; (6) Any person who have had organ transplants, or have had bone marrow or stem cell transplant in the past 6 months; (7) Any person who is about to be admitted in enclosed institutions such as jails, penitentiaries, and mental institutions.

- Residents, occupants or workers in a localized area with an active COVID-19 cluster, as identified and declared by the local chief executive in accordance with existing DOH Guidelines and consistent with the National Task Force Memorandum Circular No. 02 s.2020 or the Operational Guidelines on the Application of the Zoning Containment Strategy in the Localization of the National Action Plan Against COVID-19 Response. The local chief executive shall conduct the necessary testing in order to protect the broader community and critical economic activities and to avoid a declaration of a wider community quarantine.
- Frontliners in Tourist Zones:
- H1 All workers and employees in the hospitality and tourism sectors in El Nido, Boracay, Coron, Panglao, Siargao and other tourist zones, as identified and declared by the Department of Tourism. These workers and employees may be tested once every four (4) weeks.
- H2 All travelers, whether of domestic or foreign origin, may be tested at least once, at their own expense, prior to entry into any designated tourist zone, as identified and declared by the Department of Tourism.
- All workers and employees of manufacturing companies and public service providers registered in economic zones located in Special Concern Areas may be tested regularly.
- J Economy Workers
- J1 Frontline and Economic Priority Workers, defined as those 1) who work in high priority sectors, both public and private, 2) have high interaction with and exposure to the public, and 3) who live or work in Special Concerns Areas, may be tested every three (3) months. These include but not limited to:
 - **Transport and Logistics**: drivers of taxis, ride hailing services, buses, public transport vehicle, conductors, pilots, flight attendants, flight engineers, rail operators, mechanics, servicemen, delivery staff, water transport workers (ferries, inter-island shipping, ports)
 - Food Retails: waiters, waitress, bar attendants, baristas, chefs, cooks, restaurant managers
 - Education: teachers at all levels of education and other school frontliners such as guidance counselors, librarians, cashiers
 - Financial Services: bank tellers
 - Non-Food Retails: cashiers, stock clerks, retail salespersons
 - **Services**: hairdressers, barbers, manicurists, pedicurists, massage therapists, embalmers, morticians, undertakers, funeral directors, parking lot attendants, security guards, messengers
 - Construction: construction workers including carpenters, stonemasons, electricians, painters, foremen, supervisors, civil engineers, structural engineers, construction managers, crane/tower operators, elevator installers, repairmen
 - Water Supply, Sewerage, Waster Management: plumbers, recycling/ reclamation workers, garbage collectors, water/wastewater engineers, janitors, cleaners
 - **Public Sector**: judges, courtroom clerks, staff and security, all national and local government employees rendering frontline services in special concern areas
 - Mass Media: field reporters, photographers, cameramen
- All employees **not covered above are not required to undergo testing but are encouraged to be**12 **tested every quarter.** Private sector employers are highly encouraged to send their employees for regular testing at the employers' expense
 - in order to avoid lockdowns that may do more damage to their companies

Appendix 3. Severity of the Disease

MILD

Symptomatic patients presenting with fever, cough, fatigue, anorexia, myalgias; other non-specific symptoms such as sore throat, nasal congestion, headache, diarrhea, nausea and vomiting; loss of smell (anosmia) or loss of taste (ageusia) preceding the onset of respiratory symptoms with NO signs of pneumonia or hypoxia

MODERATE

- Adolescent or adult with clinical signs of non-severe pneumonia (e.g. fever, cough, dyspnea, respiratory rate (RR) = 21-30 breaths/minute, peripheral capillary oxygen saturation (SpO2) >92% on room air)
- Child with clinical signs of non-severe pneumonia (cough or difficulty of breathing and fast breathing [< 2 months: > 60; 2-11 months: > 50; 1-5 years: > 40] and/or chest indrawing)

SEVERE

- Adolescent or adult with clinical signs of severe pneumonia or severe acute respiratory infection as follows: fever, cough, dyspnea, RR>30 breaths/minute, severe respiratory distress or SpO2 < 92% on room air
- 2. Child with clinical signs of pneumonia (cough or difficulty in breathing) plus at least one of the following:
 - a. Central cyanosis or SpO2 < 90%; severe respiratory distress (e.g. fast breathing, grunting, very severe chest indrawing); general danger sign: inability to breastfeed or drink, lethargy or unconsciousness, or convulsions.
 - b. Fast breathing (in breaths/min): < 2 months: > 60; 2-11 months: > 50; 1-5 years: > 40.

CRITICAL

Patients manifesting with acute respiratory distress syndrome, sepsis and/or septic shock:

- 1. Acute Respiratory Distress Syndrome (ARDS)
 - a. Patients with onset within 1 week of known clinical insult (pneumonia) or new or worsening respiratory symptoms, progressing infiltrates on chest X-ray or chest CT scan, with respiratory failure not fully explained by cardiac failure or fluid overload

2. Sepsis

- a. Adults with life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection. Signs of organ dysfunction include altered mental status, difficult or fast breathing, low oxygen saturation, reduced urine output, fast heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of coagulopathy, thrombocytopenia, acidosis, high lactate or hyperbilirubinemia
- b. Children with suspected or proven infection and > 2 age-based systemic inflammatory response syndrome criteria (abnormal temperature [> 38.5 °C or < 36 °C); tachycardia for age or bradycardia for age if < 1year; tachypnea for age or need for mechanical ventilation; abnormal white blood cell count for age or > 10% bands), of which one must be abnormal temperature or white blood cell count.

3. Septic Shock

- a. Adults with persistent hypotension despite volume resuscitation, requiring vasopressors to maintain MAP > 65 mmHg and serum lactate level >2mmol/L
- o. Children with any hypotension (SBP < Sth centile or > 2 SD below normal for age) or two or three of the following: altered mental status; bradycardia or tachycardia (HR < 90 bpm or > 160 bpm in infants and heart rate < 70 bpm or > 150 bpm in children); prolonged capillary refill (> 2 sec) or weak pulse; fast breathing; mottled or cool skin or petechial or purpuric rash; high lactate; reduced urine output; hyperthermia or hypothermia.